Leadership in Respiratory Disease Therapy
Altair Therapeutics is an emerging biopharmaceutical company focusing on developing novel therapeutics to treat human respiratory diseases.
Altair is a privately owned company that was spun out of ISIS Pharmaceuticals in October 2007 with the objective of applying ISIS’s proprietary second generation (2’-MOE Gapmer) antisense oligoneucleotide technology to the field of inhaled therapeutics. Through its collaboration with ISIS Altair has access to both near term clinical stage opportunities, as well as early stage development projects.
Altair’s first compound AIR645 is currently in phase I clinical trials. This first in class compound posses unique anti-inflammatory activities appropriate for multiple therapeutic applications, including asthma, rhinitis and COPD. Additionally, the characteristics of the 2'-MOE Gapmer chemistry provides for the possibility of administration of AIR645 as an inhaled therapeutic delivered once weekly.
Altair is also planning on developing a future pipeline of other best-in-class molecules for respiratory targets by exploiting the advantages of our propriety 2nd generation antisense oligonucleotide chemistry.